A case of pediatric PTLD following autologous stem cell transplantation and review of the literature.
The development of PTLD is a rare severe adverse event following ASCT. We report on a child with DS who developed PTLD following autologous transplant for relapsed Hodgkin's disease. He was successfully treated with cyclophosphamide, prednisone and rituximab. We also present a comprehensive review of the literature of PTLD in pediatric patients following ASCT.
Eckrich
Michael J
MJ
Pediatric Hematology/Oncology, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, USA.
Frangoul
Haydar
H
Knight
Jennifer
J
Mosse
Claudio
C
Domm
Jennifer
J
D058846:Antibodies, Monoclonal, Murine-Derived / Q000494:pharmacology; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007107:Immune System; D007165:Immunosuppression Therapy / Q000009:adverse effects; D016403:Lymphoma, Large B-Cell, Diffuse / Q000628:therapy; D008232:Lymphoproliferative Disorders / Q000175:diagnosis / Q000209:etiology*; D008297:Male; D011183:Postoperative Complications / Q000175:diagnosis* / Q000209:etiology; D012074:Remission Induction; D000069283:Rituximab; D033581:Stem Cell Transplantation / Q000379:methods*; D016896:Treatment Outcome
D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab